Process and intermediates for preparing macrolactams
View Patent ↗The present invention includes compounds useful as intermediates in the preparation of macrolactams, methods for preparing the intermediates, and methods for preparing macrolactams from the intermediates. One use of the methods and intermediates described herein is in the production of macrolactam compounds able to inhibit HCV NS3 protease activity. HCV NS3 inhibitory compounds have therapeutic and research applications.
1. A method of making Compound A or a salt thereof:
comprising
the steps of:
(i) reacting
with
by SNAR replacement to form Compound 13 and deprotecting
to form
wherein Compound 13 is not isolated prior to deprotection, and PG is a protecting group;
(ii) coupling Compound 14 with
to produce
(iii) without isolating Compound 16, hydrogenating Compound 16 to produce
(iv) without isolating Compound 21, lactamizing Compound 21 to produce
(v) converting Compound 18 to
(vi) coupling
or salt thereof, to
or salt thereof,
wherein the coupling of step (vi) comprises the use of a coupling reagent and a compound selected from the group consisting of
wherein R 5 is either hydrogen, aryl, halogen, C 1-6 alkyl, O—C 1-6 alkyl or C 3 -C 8 cycloalkyl, and wherein any of Compounds 11, 12, 13, 14, 15, 16, 21, and 18 independently may be provided as salts.
2. The method of claim 1 , wherein said coupling reagent is EDC, and the method comprises the use of at least 10 equivalents of pyridine and the use of acetonitrile as solvent.
3. The method of claim 1 , wherein said coupling reagent is EDC, and the method comprises the use of THF-DMAc as solvent and a temperature range of −10° C. to 50° C.
4. A compound selected from the group consisting of: a MeCN solvate of a methylsulfonic acid salt of
wherein said solvate is characterized by an X-ray powder diffraction pattern obtained using copper Kα radiation which comprises 2Θ values in degrees of about 5.3, 12.0, and 14;
or a salt thereof.
5. The compound of claim 4 , wherein said compound is a MeCN solvate of a Compound 14 methylsulfonic acid salt, wherein said solvate is characterized by an X-ray powder diffraction pattern obtained using copper Kα radiation which comprises 2Θ values in degrees of about 5.3, 12.0, and 14.
6. A method of making a compound of claim 4 , wherein the compound is Compound 16, said method comprising the step of:
wherein Compounds 14, 15, and 16 may be provided as a salt.
7. A method of making a compound of claim 4 , wherein the compound is Compound 17, said method comprising the steps of:
wherein Compounds 14, 15, 16, and 17 may be provided as a salt, and Compound 16 is not isolated prior to lactamization.
8. A compound selected from the group consisting of
a hydrate of Compound 19
wherein said hydrate of Compound 19 is characterized by either (i) an X-ray powder diffraction pattern obtained using copper Kα radiation which comprises 2Θ values in degrees of about 8.7, 22.2, and 23.5; or (ii) a solid state carbon−13 CPMAS NMR comprising peaks at about 174.7, 172.0, 161.4, 156.8, 156.3, 149.5, 142.1, 133.9, 128.2, 121.3, 105.0, 76.9, 60.7, 57.5, 55.1, 53.5, 35.8, 34.7, 33.4, 32.4, 29.5, 27.8, 24.0, and20.2 ppm.